07:18 AM EDT, 05/29/2025 (MT Newswires) -- Immunovant ( IMVT ) reported a fiscal Q4 net loss Thursday of $0.64 per diluted share, wider than a loss of $0.52 a year earlier.

Analysts polled by FactSet expected a loss of $0.69.

As of March 31, the company said it held about $714 million in cash and cash equivalents, which will finance its current programs through a key readout in Graves' disease anticipated in 2027.